JP2025505261A - 統合失調症患者における再発の予防におけるロルペリドンの使用 - Google Patents
統合失調症患者における再発の予防におけるロルペリドンの使用 Download PDFInfo
- Publication number
- JP2025505261A JP2025505261A JP2024547680A JP2024547680A JP2025505261A JP 2025505261 A JP2025505261 A JP 2025505261A JP 2024547680 A JP2024547680 A JP 2024547680A JP 2024547680 A JP2024547680 A JP 2024547680A JP 2025505261 A JP2025505261 A JP 2025505261A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- schizophrenia
- lorperidone
- symptoms
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309874P | 2022-02-14 | 2022-02-14 | |
| US63/309,874 | 2022-02-14 | ||
| PCT/US2023/062500 WO2023154927A1 (en) | 2022-02-14 | 2023-02-13 | Use of roluperidone in preventing relapse in schizophrenia patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025505261A true JP2025505261A (ja) | 2025-02-21 |
| JP2025505261A5 JP2025505261A5 (https=) | 2026-02-20 |
Family
ID=85569991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547680A Pending JP2025505261A (ja) | 2022-02-14 | 2023-02-13 | 統合失調症患者における再発の予防におけるロルペリドンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230255953A1 (https=) |
| EP (2) | EP4479049B1 (https=) |
| JP (1) | JP2025505261A (https=) |
| KR (1) | KR20240161650A (https=) |
| CN (1) | CN118984705A (https=) |
| AU (1) | AU2023217097A1 (https=) |
| CA (1) | CA3243767A1 (https=) |
| CL (1) | CL2024002418A1 (https=) |
| ES (1) | ES3064313T3 (https=) |
| IL (1) | IL314859A (https=) |
| MX (1) | MX2024009828A (https=) |
| WO (1) | WO2023154927A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| WO2020264486A1 (en) * | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
-
2023
- 2023-02-13 EP EP23710619.0A patent/EP4479049B1/en active Active
- 2023-02-13 JP JP2024547680A patent/JP2025505261A/ja active Pending
- 2023-02-13 AU AU2023217097A patent/AU2023217097A1/en active Pending
- 2023-02-13 US US18/168,028 patent/US20230255953A1/en active Pending
- 2023-02-13 WO PCT/US2023/062500 patent/WO2023154927A1/en not_active Ceased
- 2023-02-13 EP EP25223916.5A patent/EP4729122A2/en active Pending
- 2023-02-13 KR KR1020247031088A patent/KR20240161650A/ko active Pending
- 2023-02-13 IL IL314859A patent/IL314859A/en unknown
- 2023-02-13 CA CA3243767A patent/CA3243767A1/en active Pending
- 2023-02-13 CN CN202380033205.7A patent/CN118984705A/zh active Pending
- 2023-02-13 ES ES23710619T patent/ES3064313T3/es active Active
-
2024
- 2024-08-12 CL CL2024002418A patent/CL2024002418A1/es unknown
- 2024-08-12 MX MX2024009828A patent/MX2024009828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3243767A1 (en) | 2023-08-17 |
| WO2023154927A1 (en) | 2023-08-17 |
| EP4479049B1 (en) | 2025-12-17 |
| US20230255953A1 (en) | 2023-08-17 |
| EP4729122A2 (en) | 2026-04-22 |
| IL314859A (en) | 2024-10-01 |
| AU2023217097A1 (en) | 2024-08-29 |
| CL2024002418A1 (es) | 2024-12-13 |
| EP4479049A1 (en) | 2024-12-25 |
| CN118984705A (zh) | 2024-11-19 |
| ES3064313T3 (en) | 2026-04-23 |
| MX2024009828A (es) | 2024-11-08 |
| KR20240161650A (ko) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stahl | Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline | |
| US10322119B2 (en) | Use of pridopidine for treating Huntington's disease | |
| JP2024180450A (ja) | ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法 | |
| Sheehan et al. | Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient | |
| Bostwick | A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy | |
| Findling et al. | An open-label pilot study of St. John's wort in juvenile depression | |
| US11090297B2 (en) | Pridopidine for treating huntington's disease | |
| US20250352533A1 (en) | Pridopidine for treating huntington's disease | |
| JP2022524008A (ja) | うつ病の治療のためのエスケタミン | |
| Kato et al. | Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT | |
| TW202102219A (zh) | 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法 | |
| JP2025505261A (ja) | 統合失調症患者における再発の予防におけるロルペリドンの使用 | |
| Madlung‐Kratzer et al. | A double‐blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification | |
| JP2015502941A (ja) | 少なくとも１つのｃｎｓ障害の治療、予防、および／または管理のためのルラシドン新規投与レジメンおよびその使用 | |
| AU2022228417A1 (en) | Use of luvadaxistat for the treatment of cognitive impairment | |
| Rogers et al. | Drug treatment of the psychoses | |
| KR20240110812A (ko) | 알츠하이머병과 관련된 불안을 치료하는 방법 | |
| Malik et al. | Oculogyric Crisis Following Dosage Increase of Aripiprazole: A Case Report | |
| Schwartz et al. | Mood Disorders | |
| Hazell | The treatment of bipolar disorder in children and adolescents | |
| Ciraulo et al. | Antidepressant treatment of geriatric depression | |
| Burgess et al. | Diagnosis, Clinical Features, Outcome and Treatment | |
| Coghill | Pharmacological approaches in child and adolescent mental health | |
| Reveley et al. | Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone | |
| Anghelescu et al. | Tadalafil in a patient with treatment-resistant depression and antidepressant polypharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260212 |